Dupixent (dupilumab) was the first biologic treatment approved for atopic dermatitis. It became available in 2017. It is currently approved for adults and adolescents 6 months and older with ...

Analysts predict peak annual sales of around $2.5 billion for Dupixent, which the FDA approved in March last year for eczema – known medically as moderate-to-severe atopic dermatitis – after ...

Sanofi’s new atopic dermatitis treatment Dupixent has gained EU approval ... within the general population with moderate AD and 6 adults per 100,000 with severe AD may be eligible for treatment ...

‘The #atopic_dermatitis market is heating up! #Sanofi is gearing up to challenge #Dupixent's dominance. What new treatments are on the horizon?’ Sanofi is also advancing in the AD arena with ...